Advertisement
News
Subscribe to MDT Magazine News

Seaside advances autism drug

July 26, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Seaside Therapeutics Inc. has announced positive results from a Phase 2 trial for a drug candidate to treat fragile X, the most common form of autism.

Nanoviricides files to raise funds

July 26, 2010 10:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Nanoviricides Inc., a Connecticut developer of drugs to fight challenging infectious diseases, has filed federal documents stating it is seeking to raise an indeterminate amount of funding in what appears to be a private investment in a public entity (PIPE).

Home Medical Equipment Providers Recognize Americans with Disabilities Act 20th Anniversary, Vow to Fight for Greater Access to Care

July 26, 2010 10:37 am | by Bio-Medicine.Org | Comments

ARLINGTON, Va. , July 26 /PRNewswire-USNewswire/ -- Providers of home medical equipment and services, such as wheelchairs, oxygen therapy, and diabetic supplies, are recognizing the importance of the 20th anniversary of the Americans with Disabilities Act (ADA) today. Home medical...

TOPICS:
Advertisement

Yale cell researchers win $2.5M grants

July 26, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Two Yale University scientists working on cell biology have been named as recipients of the 2010 Pioneer Award from the National Institutes of Health, with each recipient receiving a $2.5 million grant and laboratory support for five years.

TOPICS:

NxStage revenue notches up on home products sales

July 26, 2010 9:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Lawrence medical device maker NxStage Medical Inc. saw revenue for the second quarter of 2010 jump 21 percent, and managed to cut losses by nearly one third.

TOPICS:

Rest requirements for residents unlikely to improve outcomes in 2 common surgeries

July 26, 2010 9:35 am | by EurekAlert | Comments

(Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)) As the Accreditation Council for Graduate Medical Education seeks to further limit residents' work hours, a new study reports that outcomes in two common surgeries were similar among residents who...

TOPICS:

3DICs with TSV to provide power consumption and bandwith breakthrough

July 26, 2010 9:35 am | by I-Micronews | Comments

According to a nice article recently posted by David Lammers on System Level Design's blog, Through-silicon vias (TSVs) are in various stages of late development, but design and manufacturing challenges remain before companies can gain the full benefits of the third dimension.

GSI Group comes out of Chapter 11

July 26, 2010 9:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Laser technology company GSI Group Inc. reported late Friday that it had completed its planned restructuring and emerged from its Chapter 11 bankruptcy protection. The Bedford-based company has has cut its debt load from $210 million to $107 million, officials report.

Advertisement

Abbott to Feature Novel Tests and New Upgrades to Testing Platforms at American Association for Clinical Chemistry Lab Expo

July 26, 2010 8:33 am | by Bio-Medicine.Org | Comments

ANAHEIM, Calif. , July 26 /- A first-of-its-kind test that detects HIV infection earlier than ever before in the United States ; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow...

TOPICS:

Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics

July 26, 2010 8:32 am | by Bio-Medicine.Org | Comments

SANTA BARBARA, Calif. , July 26 /- Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent...

TOPICS:

Calibra Gains FDA Clearance to Market Finesse™ Insulin Patch-Pen for Three-Day Use With Novolog®

July 26, 2010 7:35 am | by Bio-Medicine.Org | Comments

REDWOOD CITY, Calif. , July 26 /- Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog ® rapid acting insulin. Combining the...

TOPICS:

Circle Biologics® Introduces Innovation in Medical Devices

July 26, 2010 7:35 am | by Bio-Medicine.Org | Comments

MINNEAPOLIS , July 26 /- Circle Biologics®, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform (APC™).  This innovative single device platform is the first of its kind to incorporate both...

TOPICS:

Brainlab Offers Real-Time Monitoring for IGRT

July 26, 2010 7:34 am | by Bio-Medicine.Org | Comments

WESTCHESTER, Ill. , July 26 /- Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM)...

TOPICS:

Medical Device Safety Tip: Air or Electric Dermatome Instruments

July 26, 2010 7:31 am | by U.S. Food & Drug Administration | Comments

FDA has received several reports of patients suffering lacerations when undergoing skin grafting procedures with air- or electric-powered Dermatome surgical instruments made by Zimmer, Inc. In one report, the device cut through to the bone and the...

TOPICS:

Orthovita gets clearance on collagen facility

July 26, 2010 4:45 am | by The Associated Press | Comments

Orthovita Inc. said Monday it received regulatory approval for a facility where it will process collagen used in Vitagel, a product used to control bleeding during surgery.The company said the Food and Drug Administration cleared a supplement for the new facility, which is located in Malvern,...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading